L. Schluckebier,O. U. Garay,M. Zukin and C. G. Ferreira. Carboplatin plus pemetrexed offers superior cost-effectiveness compared to pemetrexed in patients with advanced non-small cell lung cancer and performance status 2. Lung Cancer. 2015;89(3):10.1016/j.lungcan.2015.06.015.
